Midomafetamine

Psychedelic-assisted therapy (PAT) merges psychotherapy with psychedelic states, facilitated by substances like LSD, psilocybin, and MDMA, showing potential in treating PTSD, TRD, MDD, and other conditions. Despite being classified as Schedule I drugs, their therapeutic potential is increasingly recognized, leading to FDA Breakthrough Therapy designations for MDMA and psilocybin. Recent research suggests these substances reopen a 'critical period' in the brain, enhancing social reward learning and brain plasticity. Methodologically rigorous clinical research indicates substantial long-term symptom alleviation, with single sessions leading to significant symptom reduction and remission lasting up to twelve months. Despite regulatory challenges, ongoing research and clinical trials continue to explore and validate the therapeutic benefits of PAT.

SPN-820, an intracellular modulator of mTORC1, showed safety and efficacy in a phase IIa study for major depressive disorder. A Danish study found a 4.5-fold higher risk of sudden cardiac death in schizophrenic patients. The FDA expanded approval of sodium oxybate (Lumryz) for narcolepsy in children aged 7 and up. A cohort study identified eight forms of traumatic and adverse childhood experiences that affect psychiatric risk and cognitive ability differently. Mental illness may increase COVID-19 severity. GIP and/or GLP-1 receptor agonists reduced opioid overdose and alcohol intoxication rates in adults with opioid or alcohol use disorder. Lykos Therapeutics plans an additional phase III trial for MDMA-assisted PTSD therapy after FDA rejection. A psychiatrist recommends dementia tests for Donald Trump. Maternal prenatal cannabis use was not linked to child autism spectrum disorder. Over 2,400 Kaiser Permanente mental health workers went on strike in Southern California. Home-based transcranial direct current stimulation improved depression scores in a phase II trial. A Lancet Psychiatry Commission aims to limit harms of problematic internet usage. The FCC voted to route 988 Suicide and Crisis Lifeline calls by geolocation.

Psychedelic-assisted psychotherapy (PAP) is increasingly recognized as a breakthrough treatment for mental health issues, but lack of certification creates roadblocks for patients in Quebec. Only Alberta requires psychiatric training for PAP prescribers, while independent organizations offer training not recognized by Health Canada or INSPQ. Health Canada's Special Access Program allows access to psilocybin and MDMA for serious conditions, but the application process is invasive and confusing. The absence of official PAP certification raises concerns about the qualifications of those reviewing applications, potentially delaying or denying access to life-altering treatments.

PharmAla Biotech Holdings Inc. contracted as supplier of GMP LaNeo™ MDMA for clinical trial at Mt. Sinai Health System. Termination of supply agreement with CCrest Labs. PharmAla focuses on research, development, and manufacturing of MDXX class molecules, including MDMA.

Massachusetts may legalize certain plant-based psychedelics on Nov. 5, following Oregon and Colorado. The Natural Psychedelic Substances Act aims to regulate access to psilocybin, DMT, mescaline, and ibogaine at licensed therapy centers. Experts warn of safety and purity concerns, suggesting FDA approval of purified, synthetic molecules is the safest path. Despite potential implementation challenges, state initiatives and pharmaceutical development may coexist.

Ibogaine induces intense hallucinations, while tabernanthalog, a non-hallucinogenic analogue, offers altered states without trips. The definition of a trip is evolving as researchers develop non-hallucinogenic psychedelics for medical use, raising questions about what constitutes a psychedelic experience.

Saint Lucia launched an Early Warning System (EWS) to monitor drug-related threats, involving a network of experts and agencies. The EWS issues alerts for health-related trends linked to illegal drugs, as demonstrated by its success in other Caribbean islands. The system relies on information from various sectors and aims to improve public health and safety.

The Ministry of Health, Wellness, and Elderly Affairs, in collaboration with the OAS, launched an Early Warning System (EWS) in Saint Lucia to monitor and address emerging drug threats. The EWS, a multi-agency network, aims to facilitate rapid communication and enhance intervention strategies. Ching-Soto of the OAS emphasized the urgency of the initiative, highlighting Saint Lucia's role as a transit point for drug trafficking and the potential infiltration of synthetic drugs. The EWS launch marks a significant milestone in combating the growing drug issue, reflecting the commitment of Saint Lucia's government and stakeholders.

The article discusses psilocybin's classification, therapeutic potential, and varying state laws. It highlights the growing interest in psychedelics for treating conditions like depression and PTSD. The article also addresses the legality of microdosing psilocybin, noting its federal illegality but varying state and local enforcement priorities. It provides examples of cities in California that have made psilocybin use a low enforcement priority. The article concludes with recommendations for employers dealing with employees microdosing at work, emphasizing the importance of clear policies and a safe workplace.